Department of Health and Human Services August 22, 2019 – Federal Register Recent Federal Regulation Documents
Results 1 - 11 of 11
Meeting of the National Advisory Council on Migrant Health
In accordance with the Federal Advisory Committee Act, this notice announces that the Secretary's National Advisory Council on Migrant Health (NACMH) has scheduled a public meeting. Information about NACMH and the agenda for this meeting can be found on the NACMH website at https://bphc.hrsa.gov/qualityimprovement/ strategicpartnerships/nacmh/.
Agency Information Collection Activities: Proposed Collection; Comment Request
This notice announces the intention of the Agency for Healthcare Research and Quality (AHRQ) to request that the Office of Management and Budget (OMB) approve the proposed information collection project ``Outcome Measure Harmonization and Data Infrastructure for Patient Centered Outcomes Research in Depression.''
Informational Meeting: The Importation of Infectious Biological Agents, Infectious Substances and Vectors; Public Webcast
The Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS), is hosting a public webcast to address import permit regulations for infectious biological agents, infectious substances, and vectors. Besides CDC, presenters for this webcast may include representatives from the U.S. Department of Transportation, U.S. Department of Agriculture, Department of Homeland Security, and U.S. National Authority for Containment (NAC) of Polioviruses.
Standards for Future Opioid Analgesic Approvals and Incentives for New Therapeutics To Treat Pain and Addiction; Public Hearing; Correction
The Food and Drug Administration (FDA) is correcting a notice entitled ``Standards for Future Opioid Analgesic Approvals and Incentives for New Therapeutics To Treat Pain and Addiction; Public Hearing'' that appeared in the Federal Register of June 21, 2019. The document was published with incorrect presenter registration and slide deck submission deadlines. This document corrects those deadlines.
Determination That ZONEGRAN (Zonisamide) Capsules, 50 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA or Agency) has determined that ZONEGRAN (zonisamide) capsules, 50 milligrams (mg), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.
Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; the Stem Cell Therapeutic Outcomes Database, OMB No. 0915-0310-Revision
In compliance with of the Paperwork Reduction Act of 1995, HRSA has submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
